1. Home
  2. UCAR vs SER Comparison

UCAR vs SER Comparison

Compare UCAR & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$0.61

Market Cap

35.5M

ML Signal

HOLD

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$2.45

Market Cap

42.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UCAR
SER
Founded
2013
2017
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
42.0M
IPO Year
2022
2024

Fundamental Metrics

Financial Performance
Metric
UCAR
SER
Price
$0.61
$2.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$50.00
$15.00
AVG Volume (30 Days)
189.6K
55.5K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$130,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.14
52 Week Low
$0.04
$1.22
52 Week High
$2.78
$5.83

Technical Indicators

Market Signals
Indicator
UCAR
SER
Relative Strength Index (RSI) 34.55 51.10
Support Level $0.52 $2.51
Resistance Level $1.66 $2.95
Average True Range (ATR) 0.09 0.19
MACD 0.00 -0.04
Stochastic Oscillator 27.93 0.00

Price Performance

Historical Comparison
UCAR
SER

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: